Another drug is the LMTM (TRx0237)—a second-generation tau protein aggregation inhibitor currently being tested in a phase-3 clinical trial (trial number: NCT03446001) for treating AD and frontotemporal dementia44. Here, YWHAQ is linked to Alzheimer disease.